Atezolizumab (Tecentriq, Tecentriq Hybreza) Coverage Criteria
Customize your policy alerts
Sign up for Anthem Policy CC-0128 alerts
Get alerted when Policy CC-0128 changes without checking for updates manually.
Monitor payer policy activity
Clinical medical policy governing medical-benefit coverage and prior authorization criteria for atezolizumab products (Tecentriq and Tecentriq Hybreza) for oncology indications, applicable to Anthem members.
Added Tecentriq Hybreza step therapy and step therapy table.
Removed age criteria for alveolar soft part sarcoma (ASPS) and combined Tecentriq and Tecentriq Hybreza criteria.
Step therapy table updates.
Modified non-squamous NSCLC criteria to allow use for actionable molecular markers and PD-L1 expression and to permit subsequent line or maintenance therapy; added mesothelioma criteria and updated do not approve criteria.
Updated hepatocellular carcinoma Child-Pugh scoring language and added indications for alveolar soft part sarcoma and mesothelioma; retired certain quantity limits.
Clarified NSCLC staging and removed platinum and ECOG requirements for some NSCLC indications; added stage IIIB inclusion.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.